Intravesical MgSO4 for the treatment of BCG refractory T1 G3 bladder cancer: Preliminary results on efficacy and safety.

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL
M. Moussa, M. Chakra, I. Duquesne
{"title":"Intravesical MgSO4 for the treatment of BCG refractory T1 G3 bladder cancer: Preliminary results on efficacy and safety.","authors":"M. Moussa, M. Chakra, I. Duquesne","doi":"10.5582/irdr.2022.01057","DOIUrl":null,"url":null,"abstract":"An urgent need of therapy exists for patients with high-risk non-muscle invasive bladder cancer (NMIBC) for whom Bacillus Calmette-Guérin (BCG) refractory treatment has failed. We investigated the role of intravesical magnesium sulfate (MgSO4) therapy in the management of BCG refractory T1 high grade (G3) NMIBC. Between January 2018 and July 2021, we performed a prospective trial enrolling participants with T1 G3 NMIBC refractory in BCG therapy. All patients included were considered ineligible for or have refused to undergo radical cystectomy. Subjects are enrolled into a single treatment group of a fixed dose of intravesical MgSO4. The intravesical solution was given for 3 h bi-weekly × 6 then once per week for 12 months. Cystoscopic surveillance was performed every 3 months. Endoscopic resection was performed if suspicious findings were identified on surveillance cystoscopy to establish pathologic diagnosis. Oncological outcomes and any side effects were reported during follow-up. A total of 8 patients who received intravesical MgSO4 for refractory TG3 tumors were included in our study. The median follow-up time was 29 months (range from 23 to 36). 62.5% of the patients (5/8) achieved a complete response to intravesical MgSO4, while 25% of the patients (2/8) had a partial response and 12.5% (1/8) had persistent disease. None of the patients had disease progression. None of the patients experienced hypermagnesemia. In patients with pTG3 tumors who were refractory to BCG therapy, intravesical MgSO4 was a well-tolerated and potentially effective regimen.","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intractable & rare diseases research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5582/irdr.2022.01057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

An urgent need of therapy exists for patients with high-risk non-muscle invasive bladder cancer (NMIBC) for whom Bacillus Calmette-Guérin (BCG) refractory treatment has failed. We investigated the role of intravesical magnesium sulfate (MgSO4) therapy in the management of BCG refractory T1 high grade (G3) NMIBC. Between January 2018 and July 2021, we performed a prospective trial enrolling participants with T1 G3 NMIBC refractory in BCG therapy. All patients included were considered ineligible for or have refused to undergo radical cystectomy. Subjects are enrolled into a single treatment group of a fixed dose of intravesical MgSO4. The intravesical solution was given for 3 h bi-weekly × 6 then once per week for 12 months. Cystoscopic surveillance was performed every 3 months. Endoscopic resection was performed if suspicious findings were identified on surveillance cystoscopy to establish pathologic diagnosis. Oncological outcomes and any side effects were reported during follow-up. A total of 8 patients who received intravesical MgSO4 for refractory TG3 tumors were included in our study. The median follow-up time was 29 months (range from 23 to 36). 62.5% of the patients (5/8) achieved a complete response to intravesical MgSO4, while 25% of the patients (2/8) had a partial response and 12.5% (1/8) had persistent disease. None of the patients had disease progression. None of the patients experienced hypermagnesemia. In patients with pTG3 tumors who were refractory to BCG therapy, intravesical MgSO4 was a well-tolerated and potentially effective regimen.
膀胱内硫酸镁治疗BCG难治性T1 G3膀胱癌症:疗效和安全性的初步结果。
对于卡介苗(BCG)难治性治疗失败的高危非肌肉浸润性膀胱癌(NMIBC)患者,迫切需要治疗。我们研究了膀胱内硫酸镁(MgSO4)治疗在治疗BCG难治性T1高级别(G3) NMIBC中的作用。在2018年1月至2021年7月期间,我们进行了一项前瞻性试验,招募T1 G3 NMIBC难治性患者接受BCG治疗。所有纳入的患者都被认为不适合或拒绝接受根治性膀胱切除术。受试者被纳入单一治疗组,接受固定剂量的MgSO4静脉注射。膀胱内滴注3 h,每两周× 6次,然后每周1次,连续12个月。每3个月进行一次膀胱镜检查。如果在监视膀胱镜检查中发现可疑的发现,则进行内镜切除以建立病理诊断。随访期间报告肿瘤预后和任何副作用。我们的研究共纳入了8例难治性TG3肿瘤患者接受MgSO4膀胱内灌注治疗。中位随访时间为29个月(23 ~ 36个月)。62.5%的患者(5/8)对膀胱内MgSO4达到完全缓解,而25%的患者(2/8)有部分缓解,12.5%(1/8)有持续性疾病。所有患者均无疾病进展。所有患者均未出现高镁血症。对于卡介苗治疗难治性的pTG3肿瘤患者,膀胱MgSO4是一种耐受性良好且潜在有效的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Intractable & rare diseases research
Intractable & rare diseases research MEDICINE, GENERAL & INTERNAL-
CiteScore
2.10
自引率
0.00%
发文量
29
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信